Strata Critical Medical (SRTA) Cost of Revenue (2021 - 2026)

Strata Critical Medical (SRTA) has 6 years of Cost of Revenue data on file, last reported at $53.3 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $53.3 million, up 84.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $247.5 million (up 9.88% YoY), and the FY2025 annual result was $156.0 million, up 33.09% from the prior year.
• Cost of Revenue fell to $53.3 million in Q1 2026 per SRTA's latest filing, from $154.9 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $175.0 million in Q4 2023 and troughed at $1.6 million in Q2 2025.
• A 5-year average of $55.1 million and a median of $38.1 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue surged 2017.06% in 2023, then slumped 96.83% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $30.5 million in 2022, then jumped by 473.47% to $175.0 million in 2023, then plunged by 33.61% to $116.2 million in 2024, then jumped by 33.32% to $154.9 million in 2025, then plunged by 65.62% to $53.3 million in 2026.
• Business Quant data shows SRTA's Cost of Revenue at $53.3 million in Q1 2026, $154.9 million in Q4 2025, and $37.7 million in Q3 2025.